کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3978563 1257287 2014 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Exémestane-évérolimus dans les cancers du sein métastatiques de la femme ménopausée, HER2-négatifs, exprimant les récepteurs hormonaux et résistants aux inhibiteurs de l'aromatase non stéroïdiens : une nouvelle option thérapeutique
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Exémestane-évérolimus dans les cancers du sein métastatiques de la femme ménopausée, HER2-négatifs, exprimant les récepteurs hormonaux et résistants aux inhibiteurs de l'aromatase non stéroïdiens : une nouvelle option thérapeutique
چکیده انگلیسی
Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is commonly deregulated in breast cancer and has been involved in resistance to endocrine therapy. In the BOLERO-2 study, the addition of everolimus, a selective inhibitor of mTOR protein, to exemestane was associated with a significant improvement in progression-free survival, compared to exemestane plus placebo, in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, and resistant to non-steroidal aromatase inhibitor therapy. However, adverse events and treatment stops were more often observed with the combination therapy, suggesting the need for a careful benefit/risk evaluation before initiating this new combination. This review aims at synthesizing the biological basis of the everolimus-exemestane association, presenting the main validated and ongoing therapeutic trials, interests and limits, as well as the multiple potential therapeutic perspectives.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bulletin du Cancer - Volume 101, Issue 3, March 2014, Pages 325-333
نویسندگان
, , ,